HRP20241297T1 - Optimizirani sistem domaćina / vektora za stvaranje zaštitnih mono- i viševalentnih podjedinica cjepiva na bazi kvasca kluyveromyces lactis - Google Patents

Optimizirani sistem domaćina / vektora za stvaranje zaštitnih mono- i viševalentnih podjedinica cjepiva na bazi kvasca kluyveromyces lactis Download PDF

Info

Publication number
HRP20241297T1
HRP20241297T1 HRP20241297TT HRP20241297T HRP20241297T1 HR P20241297 T1 HRP20241297 T1 HR P20241297T1 HR P20241297T T HRP20241297T T HR P20241297TT HR P20241297 T HRP20241297 T HR P20241297T HR P20241297 T1 HRP20241297 T1 HR P20241297T1
Authority
HR
Croatia
Prior art keywords
lactis
lactis strain
strain
locus
promoter
Prior art date
Application number
HRP20241297TT
Other languages
English (en)
Croatian (hr)
Inventor
Hans Caspar HÜHRLIMANN
Martina Behrens
Mandy Gebauer
Karin Breunig
Sven-Erik Behrens
Original Assignee
Verovaccines Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Verovaccines Gmbh filed Critical Verovaccines Gmbh
Publication of HRP20241297T1 publication Critical patent/HRP20241297T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14—Fungi; Culture media therefor
    • C12N1/16—Yeasts; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C12N15/815—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts for yeasts other than Saccharomyces
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/10011—Birnaviridae
    • C12N2720/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
    • C12N2770/24334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Botany (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Nutrition Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
HRP20241297TT 2017-12-27 2018-12-19 Optimizirani sistem domaćina / vektora za stvaranje zaštitnih mono- i viševalentnih podjedinica cjepiva na bazi kvasca kluyveromyces lactis HRP20241297T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102017012109.5A DE102017012109A1 (de) 2017-12-27 2017-12-27 Optimiertes Wirts-/Vektorsystem zur Erzeugung protektiver mono- und multivalenter subunit-Vakzine auf Basis der Hefe Kluyveromyces lactis
PCT/DE2018/000379 WO2019129321A2 (de) 2017-12-27 2018-12-19 Optimiertes wirts-/vektorsystem zur erzeugung protektiver mono- und multivalenter subunit-vakzine auf basis der hefe kluyveromyces lactis
EP18857443.8A EP3732293B1 (de) 2017-12-27 2018-12-19 Optimiertes wirts-/vektorsystem zur erzeugung protektiver mono- und multivalenter subunit-vakzine auf basis der hefe kluyveromyces lactis

Publications (1)

Publication Number Publication Date
HRP20241297T1 true HRP20241297T1 (hr) 2024-12-20

Family

ID=65817691

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20241297TT HRP20241297T1 (hr) 2017-12-27 2018-12-19 Optimizirani sistem domaćina / vektora za stvaranje zaštitnih mono- i viševalentnih podjedinica cjepiva na bazi kvasca kluyveromyces lactis

Country Status (18)

Country Link
US (2) US11905517B2 (enExample)
EP (1) EP3732293B1 (enExample)
JP (2) JP7782951B2 (enExample)
KR (1) KR102704217B1 (enExample)
CN (1) CN111801422B (enExample)
BR (1) BR112020013245A2 (enExample)
CA (1) CA3086598A1 (enExample)
DE (2) DE102017012109A1 (enExample)
DK (1) DK3732293T3 (enExample)
EA (1) EA202091435A1 (enExample)
ES (1) ES2990197T3 (enExample)
HR (1) HRP20241297T1 (enExample)
HU (1) HUE068358T2 (enExample)
MX (1) MX2020006846A (enExample)
PL (1) PL3732293T3 (enExample)
PT (1) PT3732293T (enExample)
WO (1) WO2019129321A2 (enExample)
ZA (1) ZA202003553B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4001417A1 (en) * 2020-11-13 2022-05-25 serYmun Yeast GmbH Yeast platform for the production of vaccines
CN119391747B (zh) * 2024-12-12 2025-11-18 华中农业大学 一种利用马克斯克鲁维酵母制备禽传染性法氏囊病vp2纳米颗粒口服疫苗的方法及应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830463A (en) 1993-07-07 1998-11-03 University Technology Corporation Yeast-based delivery vehicles
US7083787B2 (en) 2000-11-15 2006-08-01 Globeimmune, Inc. Yeast-dendritic cell vaccines and uses thereof
CA2508957C (en) 2002-12-16 2015-11-17 Globeimmune, Inc. Yeast-based vaccines as immunotherapy
BRPI0516356A (pt) 2004-10-18 2008-09-02 Globeimmune Inc terapia à base de levedura para infecções crÈnicas da hepatite c
SG169375A1 (en) 2006-02-02 2011-03-30 Globeimmune Inc Yeast-based vaccine for inducing an immune response
DE102008057451A1 (de) 2008-11-14 2010-05-20 Martin-Luther-Universität Halle-Wittenberg Verfahren zur oralen Vakzinierung mittels rekombinanter Hefen
KR101781966B1 (ko) 2009-04-17 2017-09-27 글로브이뮨 암에 대한 병용 면역요법 조성물 및 방법
DE102011121069A1 (de) 2011-12-13 2013-06-13 Martin-Luther-Universität Halle-Wittenberg Vakzinierung mittels rekombinanter Hefe durch Erzeugung einer protektiven humoralen Immunantwort gegen definierte Antigene

Also Published As

Publication number Publication date
KR20200104367A (ko) 2020-09-03
KR102704217B1 (ko) 2024-09-09
WO2019129321A2 (de) 2019-07-04
CA3086598A1 (en) 2019-07-04
JP7782951B2 (ja) 2025-12-09
PT3732293T (pt) 2024-10-09
JP2021508496A (ja) 2021-03-11
MX2020006846A (es) 2020-11-06
DE112018006647A5 (de) 2020-10-01
HUE068358T2 (hu) 2024-12-28
ZA202003553B (en) 2021-06-30
ES2990197T3 (es) 2024-11-29
DK3732293T3 (da) 2024-09-23
DE102017012109A1 (de) 2019-06-27
CN111801422A (zh) 2020-10-20
WO2019129321A3 (de) 2019-09-12
EP3732293A2 (de) 2020-11-04
PL3732293T3 (pl) 2024-11-18
US20240102031A1 (en) 2024-03-28
US11905517B2 (en) 2024-02-20
BR112020013245A2 (pt) 2020-12-01
EA202091435A1 (ru) 2020-08-28
EP3732293B1 (de) 2024-07-03
CN111801422B (zh) 2024-06-14
JP2023166412A (ja) 2023-11-21
US20210230612A1 (en) 2021-07-29
US12473562B2 (en) 2025-11-18

Similar Documents

Publication Publication Date Title
Mancera Gracia et al. Influenza A virus in swine: epidemiology, challenges and vaccination strategies
Plotkin Vaccines, vaccination, and vaccinology
de Vries et al. Viral vector-based influenza vaccines
Bande et al. Progress and challenges toward the development of vaccines against avian infectious bronchitis
Lo et al. Comparison of vaccines for induction of heterosubtypic immunity to influenza A virus: cold-adapted vaccine versus DNA prime-adenovirus boost strategies
Ulmer Influenza DNA vaccines
Stachyra et al. DNA vaccines against influenza.
Elkashif et al. Adenoviral vector‐based platforms for developing effective vaccines to combat respiratory viral infections
JP2017503482A5 (enExample)
ZA200704088B (en) Recombinant influenza vectors with tandem transcription units
JP2008522621A (ja) 世界的に流行するトリインフルエンザに対して迅速に応答するためのワクチン
de Swart et al. Advantages and challenges of Newcastle disease virus as a vector for respiratory mucosal vaccines
Olszewska et al. Protective and disease-enhancing immune responses induced by recombinant modified vaccinia Ankara (MVA) expressing respiratory syncytial virus proteins
WO2006073431A3 (en) Avipox recombinants expressing foot and mouth disease virus genes
HRP20241297T1 (hr) Optimizirani sistem domaćina / vektora za stvaranje zaštitnih mono- i viševalentnih podjedinica cjepiva na bazi kvasca kluyveromyces lactis
Yu et al. Enhanced immune responses using plasmid DNA replicon vaccine encoding the Hc domain of Clostridium botulinum neurotoxin serotype A
Gasparini et al. Live attenuated influenza vaccine–a review
Loomis et al. Gene-based vaccine approaches for respiratory syncytial virus
Di et al. The self-assembled nanoparticle-based multi-epitope influenza mRNA vaccine elicits protective immunity against H1N1 and B influenza viruses in mice
CN113164582A (zh) 嵌合黄病毒丽沙病毒疫苗
CN117535322A (zh) 具有异源抗原的活的减毒黄病毒
Kennedy et al. Update on Influenza Vaccines: needs and progress
JP2021508496A5 (enExample)
Babuadze et al. A novel DNA platform designed for vaccine use with high transgene expression and immunogenicity
CN102741414B (zh) 通过重组酵母口服/粘膜接种疫苗的方法